Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary MethylGene Announces Management Changes View HTML
Toggle Summary MethylGene Reports Fourth Quarter and Full Year 2012 Financial Results View HTML
Toggle Summary MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO View HTML
Toggle Summary MethylGene Completes Enrollment in Phase II Trial of MGCD290
Topline results anticipated in the first calendar quarter of 2013
View HTML
Toggle Summary MethylGene Closes Cdn.$26.1 Million Private Placement View HTML
Toggle Summary MethylGene Reports Third Quarter 2012 Financial Results and Provides Corporate Update View HTML
Toggle Summary MethylGene Announces Cdn.$26.1 Million Private Placement
NOT FOR DISSEMINATION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
View HTML
Toggle Summary MethylGene Announces the Appointment of Dr. Charles M. Baum as President and CEO and Changes to The Board Of Directors View HTML
Toggle Summary MethylGene Presents MGCD265 Data at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics View HTML
Toggle Summary MethylGene to Present MGCD265 Data at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics View HTML